Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vera TherapeuticsVERA +3.25%35 3-1 Month Momentum % is 8.21% as of Aug. 22, 2026. GuruFocus rates VERA with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, Vera Therapeutics ranks better than 73.74% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), Vera Therapeutics's 3-1 Month Momentum % is 8.21%.
The industry rank for Vera Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
VERA's 3-1 Month Momentum % is ranked better than 73.74% of 1386
companies
in the Biotechnology industry
Industry Median: -7.01
vs VERA: 8.21
Vera Therapeutics (NAS:VERA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vera Therapeutics 3-1 Month Momentum % Related Terms
VERA vs TARS, IMNM, BEAM: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Vera Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vera Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vera Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vera Therapeutics's 3-1 Month Momentum % falls into.
Vera Therapeutics (NAS:VERA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vera Therapeutics (VERA) has a 3-1 Month Momentum % of 8.21% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vera Therapeutics and its competitors. According to the industry distribution chart, Vera Therapeutics ranks #364 out of 1386 companies in the Biotechnology industry, placing it in the top 26.3%.
Is Vera Therapeutics' 3-1 Month Momentum % too high?
Vera Therapeutics' current 3-1 Month Momentum % is 8.21%. Based on the distribution chart, Vera Therapeutics ranks #364 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vera Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Vera Therapeutics' 3-1 Month Momentum % compare to TARS and IMNM?
According to the Biotechnology industry distribution chart, Vera Therapeutics ranks #364 out of 1386 companies for 3-1 Month Momentum %. This puts Vera Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vera Therapeutics and its competitors. Vera Therapeutics's current 3-1 Month Momentum % is 8.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vera Therapeutics stock overvalued right now?
Vera Therapeutics (VERA) has a current 3-1 Month Momentum % of 8.21%. The current 3-1 Month Momentum % is 8.21%. Vera Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vera Therapeutics (VERA), the current 3-1 Month Momentum % is 8.21% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
35GF Score
Get the complete analysis for VERA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VERA has been successfully added to your 
